Jefferies initiated coverage of Akebia (AKBA) with a Buy rating and $6 price target Akebia is a commercial-stage biotech specializing in kidney disease, the analyst tells investors in a research note. The company’s initial U.S. launch of Vafseo under the Transitional Drug Add-on Payment Adjustment is looking encouraging with potential durable sales post the TDAPA, the analyst tells investors in a research note. Jefferies says the company has a few early pipeline products with upside potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics: Promising Growth Potential with Vafseo Leading the Charge
- Akebia Therapeutics Announces Public Offering Pricing
- Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz
- Morning Movers: Designer Brands jumps, Accenture falls after quarterly results
- Akebia 25M share Spot Secondary priced at $2.00